MA38296B2 - Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations - Google Patents

Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations

Info

Publication number
MA38296B2
MA38296B2 MA38296A MA38296A MA38296B2 MA 38296 B2 MA38296 B2 MA 38296B2 MA 38296 A MA38296 A MA 38296A MA 38296 A MA38296 A MA 38296A MA 38296 B2 MA38296 B2 MA 38296B2
Authority
MA
Morocco
Prior art keywords
inhibitor peptides
selective nox
prevention
treatment
novel peptides
Prior art date
Application number
MA38296A
Other languages
English (en)
Inventor
Hamid Reza Rezvani
Frédéric Mazurier
Alain Taieb
L'emira Ghida Harfouche
Original Assignee
Inst Nat Sante Rech Med
Univ Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47458818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38296(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med, Univ Bordeaux filed Critical Inst Nat Sante Rech Med
Publication of MA38296B2 publication Critical patent/MA38296B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/03—Oxidoreductases acting on NADH or NADPH (1.6) with oxygen as acceptor (1.6.3)
    • C12Y106/03001—NAD(P)H oxidase (1.6.3.1), i.e. NOX1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Abstract

La présente invention concerne de nouveaux peptides, des compositions et des procédés pour la prévention et/ou le traitement d'états pathologiques et de maladies associées à l'activité de la napdh oxydase 1 (nox1) et/ou à la production accrue d'espèces réactives de l'oxygène (ros). Les nouveaux peptides sont ainsi particulièrement utiles pour le traitement et/ou la prévention du cancer, de l'athérosclérose, de l'angiogenèse et du vieillissement.
MA38296A 2013-01-03 2014-01-03 Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations MA38296B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13150187.6A EP2752196A1 (fr) 2013-01-03 2013-01-03 Peptides inhibiteurs nox-1 sélectifs et leurs utilisations
PCT/EP2014/050063 WO2014106649A1 (fr) 2013-01-03 2014-01-03 Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA38296B2 true MA38296B2 (fr) 2019-10-31

Family

ID=47458818

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38296A MA38296B2 (fr) 2013-01-03 2014-01-03 Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations

Country Status (14)

Country Link
US (2) US20170000842A9 (fr)
EP (2) EP2752196A1 (fr)
JP (1) JP6488237B2 (fr)
CN (1) CN105007933A (fr)
AU (1) AU2014204309B2 (fr)
BR (1) BR112015015242B1 (fr)
CA (1) CA2894576A1 (fr)
DK (1) DK2941268T3 (fr)
HU (1) HUE050715T2 (fr)
IL (1) IL239762B (fr)
MA (1) MA38296B2 (fr)
RU (1) RU2699726C2 (fr)
TN (1) TN2015000295A1 (fr)
WO (1) WO2014106649A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3034500A1 (fr) 2014-12-17 2016-06-22 Genkyotex Sa Dérivés d'amido-thiazole en tant qu'inhibiteurs d'oxydase NADPH
JP6472693B2 (ja) * 2015-03-24 2019-02-20 株式会社荏原製作所 基板処理装置
US20170110622A1 (en) * 2015-10-14 2017-04-20 Solarcity Corporation Apparatus for electroplating of electrodes on photovoltaic structures
WO2019023263A1 (fr) * 2017-07-25 2019-01-31 Immune Pharmaceuticals, Inc. Procédés et compositions permettant de traiter des tumeurs comprenant un gène de fusion bcr-abl1
EP3628669A1 (fr) 2018-09-28 2020-04-01 GenKyoTex Suisse SA Nouveaux composés en tant qu'inhibiteurs de la nadph oxydase
PE20211546A1 (es) * 2018-10-05 2021-08-16 Pfizer Inhibidores de pde4 que contienen boro
CN113773394B (zh) * 2020-06-10 2023-10-27 山东大学 一种融合肽及在制备抗肿瘤制剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593966A (en) * 1989-03-31 1997-01-14 The United States Of America As Represented By The Department Of Health And Human Services Peptide derivatives of cytochrome b558 and their use as medicaments
US5726155A (en) * 1993-08-02 1998-03-10 The Scripps Research Institute Regulation of oxidative burst using LMWG-derived peptides and analogs
GB2285047B (en) * 1993-12-21 1998-04-15 Yamanouchi U K Ltd Polypeptides which inhibit the NADPH oxidase complex
EP0750630A4 (fr) * 1994-03-11 1998-01-07 Ariad Pharma Inc Procedes et materiaux d'identification d'inhibiteurs d'interactions moleculaires induites par les domaines sh3
AU3146095A (en) * 1994-07-22 1996-02-22 University Of North Carolina At Chapel Hill, The Src sh3 binding peptides and methods of isolating and using same
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6713605B1 (en) * 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
JP2005168329A (ja) * 2003-12-08 2005-06-30 Hokkaido Univ Ｎａｄｐｈオキシダーゼ活性を阻害するポリペプチド
US7582606B2 (en) * 2005-11-03 2009-09-01 The Board Of Regents Of The University Of Texas System Nadph oxidase cytosolic cofactor mutant
WO2008109833A2 (fr) * 2007-03-07 2008-09-12 University Of Florida Research Foundation, Inc. Polynucléotides et polypeptides identifiés par criblage iviat et procédés d'utilisation
JP2011515466A (ja) * 2008-03-28 2011-05-19 ニュースキン インターナショナル インコーポレイテッド 反応性酸素種の阻害のためのａｒｎｏｘ阻害物質を含む組成物
WO2013074816A2 (fr) 2011-11-15 2013-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nouveaux inhibiteurs de nox1

Also Published As

Publication number Publication date
CN105007933A (zh) 2015-10-28
IL239762A0 (en) 2015-08-31
US20170000842A9 (en) 2017-01-05
TN2015000295A1 (en) 2016-10-03
EP2752196A1 (fr) 2014-07-09
CA2894576A1 (fr) 2014-07-10
EP2941268A1 (fr) 2015-11-11
DK2941268T3 (da) 2020-09-28
US10517919B2 (en) 2019-12-31
US20170340697A1 (en) 2017-11-30
WO2014106649A1 (fr) 2014-07-10
AU2014204309A1 (en) 2015-07-09
RU2699726C2 (ru) 2019-09-09
RU2015132087A (ru) 2017-02-06
EP2941268B1 (fr) 2020-06-24
HUE050715T2 (hu) 2021-01-28
AU2014204309B2 (en) 2018-03-01
IL239762B (en) 2020-04-30
BR112015015242B1 (pt) 2020-10-27
JP2016505612A (ja) 2016-02-25
JP6488237B2 (ja) 2019-03-20
US20160030503A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
MA38296B2 (fr) Peptides inhibiteurs sélectifs de nox-1 et leurs utilisations
MX2021012669A (es) Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehido.
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA39193B1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
EA201792047A1 (ru) Новые соединения
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
WO2017015622A8 (fr) Protéines de liaison à gdf11 et leurs utilisations
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201490052A1 (ru) Соединения, ингибирующие металлоферменты
EA201490038A1 (ru) Соединения, ингибирующие металлоферменты
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
TN2014000079A1 (en) Selective and reversible inhibitors of ubiquitin specific protease 7
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA202091709A1 (ru) Ингибиторы днк-пк
EA201490030A1 (ru) Соединения, ингибирующие металлоферменты
MX2017003624A (es) Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
EA201491385A1 (ru) Соединения, ингибирующие металлоферменты
UA106640C2 (uk) Bcl-2-СЕЛЕКТИВНИЙ АПОПТОЗІНДУКУЮЧИЙ ЗАСІБ ДЛЯ ЛІКУВАННЯ РАКУ І ІМУННИХ ЗАХВОРЮВАНЬ
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
GEP20156341B (en) Anticoagulant antidotes
EA201001639A1 (ru) Композиции и способы их получения и применения